Table 1

Characteristics of HIV-HCV coinfected patients treated with antiretroviral therapy at the time of liver biopsy (parameters collected the day of the liver biopsy or during the week before)
n=184
Median age at biopsy (IQR), years 41 (36-45)
Male, n (%) 154 (84)
Ethnicity, n (%)
Caucasian 163 (89)
Black 21 (11)
Intravenous drug use, n (%) 127 (61)
Alcohol use, n (%)* 67 (36)
Median duration of HIV diagnosis (IQR, years 11 (7-14)
Median CD4 cell counts/mm3 (IQR) 321 (227-461)
Undetectable HIV RNA+, n (%) 119 (67)
HCV genotype++, n (%)
1 98 (55)
2 10 (6)
3 47 (26)
4 24 (13)
Median HCV RNA (IQR), log10 KIU/ml+++ 6.18 (5.76-6.60)
Median laboratory variables (IQR), U/l
ALT 83 (47-128)
AST 65 (43-97)
Alkaline phosphatase 89 (71-113)
GGT 80 (42-160)
Median glycemia (IQR), mmol/l 4.8 (4.3-5.3)
Glycemia 5.6mmol/l+, n (%) 33 (19)
Glycemia7.0mmol/l+, n (%) 7 (4)
Median total cholesterol (IQR), mmol/l 4.20 (3.54-5.10)
Median triglyceridemia (IQR), mmol/l 1.49 (0.99-2.10)
Triglyceridemia 1.7mmol/l+, n (%) 60 (36)
Median duration of antiretroviral therapy (IQR), months 58 (28-94)
Median cumulative exposure to antiretrovirals (IQR), months
NRTI 56 (28-90)
NNRTI 16 (9-31)
PI 23 (12-40)
Combination of ART at liver biopsy, n (%)
2 NRTI+1 PI 93 (51)
2 NRTI+1 NNRTI 36 (20)
1 or 2 NRTI 31 (16)
3 NRTI 17 (9)
Other regimens 7 (4)

+ proportions calculated on available data.

+ Data missing for 6 patients; ++ Data missing for 5 patients; +++ Data missing for 36 patients; Data missing for 11 patients; Data missing for 18 patients.

*Alcohol: no quantification was available.

Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Martinez et al.

Martinez et al. BMC Research Notes 2012 5:180   doi:10.1186/1756-0500-5-180

Open Data